Compare ACR & EQ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ACR | EQ |
|---|---|---|
| Founded | 2005 | 2017 |
| Country | United States | United States |
| Employees | 4 | 14 |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 141.1M | 129.0M |
| IPO Year | N/A | 2018 |
| Metric | ACR | EQ |
|---|---|---|
| Price | $20.29 | $2.08 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 3 |
| Target Price | ★ $24.50 | $8.00 |
| AVG Volume (30 Days) | 10.7K | ★ 400.2K |
| Earning Date | 04-29-2026 | 05-25-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $41,095,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $19.59 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $17.06 | $0.29 |
| 52 Week High | $24.61 | $2.70 |
| Indicator | ACR | EQ |
|---|---|---|
| Relative Strength Index (RSI) | 67.25 | 51.18 |
| Support Level | $18.71 | $1.60 |
| Resistance Level | $21.27 | $2.13 |
| Average True Range (ATR) | 0.34 | 0.21 |
| MACD | 0.06 | 0.01 |
| Stochastic Oscillator | 70.16 | 43.40 |
ACRES Commercial Realty Corp is a commercial real estate investment trust that focuses on originating, holding, and managing commercial real estate (CRE) mortgage loans and equity investments in commercial real estate properties through direct ownership and joint ventures. The company invests in commercial real-estate-related assets, including whole loans, A notes, B notes, mezzanine loans, and mortgage-related securities, as well as commercial finance assets, which include other asset-backed securities, senior secured corporate loans, equipment leases and notes, trust preferred securities, debt tranches of collateralized debt obligations, and private equity investments mainly issued by financial institutions.
Equillium Inc is a biotechnology innovator developing novel therapies to treat severe autoimmune and inflammatory disorders with the mission to develop life-changing therapeutics for patients. It primary goal is to advance EQ504, a novel aryl hydrocarbon receptor, or AhR, modulator, into and through clinical development. The Company operates through a single operating and reportable segment focused on the business of developing novel therapies to treat severe autoimmune and inflammatory disorders, with the mission to develop life-changing therapeutics for patients. The Company manages all business activities on a consolidated basis.